about
Myofibroblasts and lung fibrosis induced by carbon nanotube exposureEffects of Melatonin on Liver Injuries and Diseases.Lyn kinase enhanced hepatic fibrosis by modulating the activation of hepatic stellate cells.Epidermal growth factor signaling protects from cholestatic liver injury and fibrosis.Black blood T1rho MR imaging may diagnose early stage liver fibrosis: a proof-of-principle study with rat biliary duct ligation modelBone marrow-derived monocyte infusion improves hepatic fibrosis by decreasing osteopontin, TGF-β1, IL-13 and oxidative stress.A Novel Perspective on the ApoM-S1P Axis, Highlighting the Metabolism of ApoM and Its Role in Liver Fibrosis and Neuroinflammation.The Protective Effect of Heme Oxygenase-1 against Intestinal Barrier Dysfunction in Cholestatic Liver Injury Is Associated with NF-κB InhibitionAmeliorative Effects of Nilotinib on CCl4 Induced Liver Fibrosis Via Attenuation of RAGE/HMGB1 Gene Expression and Oxidative Stress in Rat.Fibrogenic Signaling Is Suppressed in Hepatic Stellate Cells through Targeting of Connective Tissue Growth Factor (CCN2) by Cellular or Exosomal MicroRNA-199a-5p.Integrins and heparan sulfate proteoglycans on hepatic stellate cells (HSC) are novel receptors for HSC-derived exosomes.Dasatinib prevent hepatic fibrosis induced by carbon tetrachloride (CCl4) via anti-inflammatory and antioxidant mechanism.The Active Components of Fuzheng Huayu Formula and Their Potential Mechanism of Action in Inhibiting the Hepatic Stellate Cells Viability - A Network Pharmacology and Transcriptomics Approach.Magnesium Isoglycyrrhizinate Ameliorates Fibrosis and Disrupts TGF-β-Mediated SMAD Pathway in Activated Hepatic Stellate Cell Line LX2P311, Friend, or Foe of Tissue Fibrosis?
P2860
Q27969008-12912C2F-F962-435D-AF77-1C8CDF874156Q33624211-1F9C11AE-0219-4DEE-AC12-59BD05E2372BQ33850253-531C7290-EA2E-45EF-85AC-82A5FBAFA983Q39446750-08FCD5FD-6FC7-4161-9D2B-719A6C2CB838Q41001675-CCAB70B8-4BAB-4095-B254-A29622527DEFQ41191069-3CCB28A4-5295-4EC7-897B-1CEAFB072BFDQ41573128-EE2E9E7F-D7D8-4684-9A2E-3A7D8E2B4634Q42072087-211D0119-0E24-4276-B7D4-2DD8D852A6C2Q42223709-3219BEB5-157B-4E1E-BB20-994D94BAAFDEQ42977945-441D0F65-C33B-4D80-B269-FC770B1104FAQ46088331-F253576A-F9A1-45DF-903D-013B5565D96AQ51033171-6D5C06B1-3FDD-4688-B760-2CD0118E9D52Q55270064-AB2774F4-70BF-4833-A186-442FA5375C75Q57492151-9DE9116D-5BC5-4634-A856-9B957DC8ACD1Q58122659-0E4AD462-58F6-4C3E-8642-9D12811C707B
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Promising Therapy Candidates for Liver Fibrosis
@ast
Promising Therapy Candidates for Liver Fibrosis
@en
Promising Therapy Candidates for Liver Fibrosis
@nl
type
label
Promising Therapy Candidates for Liver Fibrosis
@ast
Promising Therapy Candidates for Liver Fibrosis
@en
Promising Therapy Candidates for Liver Fibrosis
@nl
prefLabel
Promising Therapy Candidates for Liver Fibrosis
@ast
Promising Therapy Candidates for Liver Fibrosis
@en
Promising Therapy Candidates for Liver Fibrosis
@nl
P2093
P2860
P3181
P356
P1476
Promising Therapy Candidates for Liver Fibrosis
@en
P2093
Hsiao-Yen Ma
Shuang Liang
Tatiana Kisseleva
Yukinori Koyama
P2860
P3181
P356
10.3389/FPHYS.2016.00047
P407
P577
2016-01-01T00:00:00Z